Yulia Panina oral presentation (OB3-Tue3-1-6)
Identifying Metabolic Heterogeneity in Mammary Gland Tumours using 3D-OrbiSIMS.
1 The Francis Crick Institute - National Physical Laboratory, 1 Midland Rd, Kings Cross, Oncogenes and Tumour Metabolism Lab, NW1 1AT London, United Kingdom
2 National Physical Laboratory, Hampton Road, TW11 0LW Teddington, United Kingdom
One of the hallmarks of cancer is deregulated metabolism, often characterised by increased glucose and glutamine uptake for energetic and anabolic purposes [1, 2]. Metabolic changes contribute to well-established tumour heterogeneity, which is a major challenge for anti-cancer therapeutics . Visualising and quantifying the spatial distribution of metabolites and the activity of metabolic pathways within different tumour regions and different cell types composing a tumour as well as in surrounding healthy tissue can unveil metabolic vulnerabilities for novel or combination therapies.
Secondary Ion Mass Spectrometry (SIMS) allows mass spectrometric analysis of both the composition and structural architecture of intact tissue samples . The ability of MSI instruments to detect a broad range of biomolecules allows mapping and quantification of endogenous molecules to assess metabolic heterogeneity.
The 3D-OrbiSIMS is a new MSI instrument that can image at 240,000 mass resolving power for accurate metabolite identification and a sub-cellular lateral resolution (less than 80 nm) . We are using this instrument for specific detection, visualisation and quantification of polar and lipid metabolites in situ in normal mammary glands and mammary gland tumours.